Make your science impossible to ignore.
Bioverse turns biotech founders into the most-cited authorities in their field, attracting investors, partners, and talent through productized content systems built for life sciences.
Brilliant biotech is invisible biotech.
You have breakthrough science. A pipeline that could change lives. But the world doesn't see it, and that gap is costing you funding rounds, partnerships, and the next hire who could 10× your team.
You're losing investor rounds you should be winning
Investors fund founders they recognize. If your name doesn't surface when a biotech VC searches a thesis, you're not on the shortlist. You're not in the conversation.
Pharma deals don't materialize
BD teams at large pharma scan LinkedIn, Google, and now ChatGPT before reaching out. No digital authority means no inbound, and outbound takes 18 months longer.
The best scientists pick the loudest lab
PhDs and senior researchers join companies they admire publicly. If you're invisible online, top talent never even applies. They're already at your noisier competitor.
Productized biotech content systems for founder visibility: not retainers that drift.
Every engagement ships defined outcomes against a defined scope. No vague "social media management." No surprise invoices. No babysitting required.
From audit to authority in 90 days.
A defined four-phase system that works whether you're pre-seed or post-Series B. Predictable, measurable, designed for compounding returns.
Diagnostic Audit
Deep analysis of your current digital footprint, competitor positioning, investor visibility gaps, and AI-search presence. You receive a 30-page roadmap.
Brand & Voice System
We codify your founder voice, scientific positioning, and messaging architecture. One source of truth your team and investors can recognize anywhere.
Content Engine Launch
We ship your first 30 days of content across LinkedIn, your website, and chosen channels. Real publishing. Real engagement. Real measurement.
Authority Compounding
We optimize for the metrics that matter: investor inbounds, BD conversations, qualified inquiries. Monthly strategy reviews. Quarterly scaling decisions.
Before partnering with Bioverse, we had groundbreaking research and innovative products, but our social presence was invisible. We were missing crucial opportunities to connect with investors, partners, and even top talent. Within just 3 months, our engagement skyrocketed. They speak our language. We're no longer just another biotech company. We're a thought leader in our field.
Everything funded biotech founders ask us first.
The honest answers, no agency jargon, no vague promises.
What does Bioverse Social actually do?
We're a specialist growth partner for funded biotech and life sciences founders. We build investor visibility, thought leadership, and AI-search presence through six productized content systems: social media management, founder LinkedIn ghostwriting, content engine, SEO blog writing, GEO/AEO optimization, and website development. Every engagement runs on a defined scope with defined deliverables, no open-ended retainers, no scope creep.
Which types of biotech companies do you work with?
We work exclusively with funded biotech and life sciences companies, typically pre-seed through Series B. Our clients are founders who have strong science but limited visibility: losing investor rounds to companies with weaker data, struggling to get pharma BD conversations started, or watching top talent choose noisier competitors. If that describes your situation, we're probably the right fit.
How is biotech content marketing different from generic content marketing?
Your audience, biotech VCs, pharma BD leads, KOLs, and senior scientists, are exceptionally allergic to generic promotional content. They respond to scientific credibility, clear thinking, and demonstrated expertise. Our biotech content marketing systems are built around this reality: everything we produce is grounded in your actual science, written to be credible to a technical reader, and calibrated to the specific platforms where your target investors and partners actually spend time. Generic "10 social media tips" content would actively hurt you with this audience.
How long does it take to build meaningful investor visibility?
Most clients see meaningful inbound change, investor inquiries, partnership conversations, or speaking invitations, within 60 to 90 days. The system takes a few weeks to build momentum because it's grounded in real positioning and real content, not shortcuts. Six to twelve months in, the compounding effect becomes substantial: a content library that keeps generating inbounds, a founder LinkedIn profile that investors recognise on sight, and AI-search presence that outlasts the engagement itself.
What is GEO / AEO and why does my biotech need it?
GEO (Generative Engine Optimization) and AEO (Answer Engine Optimization) are the practices of making your company visible inside AI-generated answers, in ChatGPT, Perplexity, Google AI Overviews, and Claude. A growing percentage of investor research and BD scoping now begins with an AI query, not a Google search. If ChatGPT can't name you when asked "who's working on [your therapeutic area]?", you're invisible to a fast-growing slice of your audience. We engineer your presence in these systems through structured data, llm.txt, brand entity building, and AI-readable content reformatting.
How does the free biotech visibility audit work?
Our free 30-page audit covers your current investor visibility, LinkedIn authority, AI-search presence, and competitive positioning, benchmarked against three to five named competitors. It's delivered within 48 hours and comes with no sales call requirement and no commitment. We invest 8–12 hours per audit. We do it for free because the work speaks for itself: most founders who receive the audit understand exactly why they need Bioverse before we've said a word.
How is Bioverse different from a regular marketing agency?
Three things set us apart. First, we work exclusively with biotech and life sciences, we understand the science, the regulatory context, the investor landscape, and the BD dynamics. Most agencies don't. Second, everything is productized: defined scope, defined outputs, defined timelines. You always know what you're getting and when. Third, we optimize for outcomes that matter in biotech specifically, investor inbounds, pharma BD conversations, and qualified talent applications, not impressions and follower counts that look good in a deck but move nothing in the real world.
Find out what your biotech's investor visibility is missing, in 48 hours.
Get a free, 30-page diagnostic audit of your digital authority, investor visibility, and AI-search presence. No sales call required. No commitment. Just clarity.
